Novartis puts pressure on Roche with cheap copy of Rituxan
Add BT as a preferred sourceZurich
SWITZERLAND'S Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.
Rixathon, from Novartis's Sandoz generics unit, follows Celltrion's Truxima that secured the European Commission's blessing in February to be used against diseases including non-Hodgkin's lymphoma and rheumatoid arthritis that are now treated by Roche's Rituxan.
TRENDING NOW
NDR 2026: Singapore to create new Western island to support 'new generation of industries'
MSCI drops S-E Asian heavyweights Sembcorp, GoTo and Ayala Land from global benchmarks
E-commerce is killing ‘real’ commerce, says China’s beverage king Zhong Shanshan
Asia-Pacific aviation: is up really the only way?
